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Introduction
Recently, the Republic of Moldova is placed among the 
countries, which show a continuous increase in the number 
of adults infected with human immunodeficiency virus 
(HIV). Rates of newly-diagnosed HIV infections vary wide-
ly across countries of Europe, Moldova being ranked the 4th 
after Russia, Ukraine and Belarus (in 2018 – 22.3 per 100 000 
population; 905 new cases) according to WHO data [1, 2]. 
There are alarming data regarding the delayed diagnosis 
(at the stage of acquired immunodeficiency syndrome), in-
volving a large number of patients with CD4 T lymphocyte 
levels below 200/mm3. In 2018 out of 696 primary identi-
fied cases, 85% (592 patients) were tested for CD4 level, of 
whom 223 were at the last HIV infection stage with CD4 
below 200/mm3 [2]. Lung infections are among the main 
manifestations for which patients seek medical advice, it is 
also a common cause of mortality in AIDS (acquired im-
munodeficiency syndrome) cases.
Both primary and secondary immunodeficiencies should 
be suspected in all cases of identified primary bronchiecta-
sis, especially in adult patients under 40 years of age [3, 4]. 
Untreated HIV infection is characterized by a progressive 
decrease level of helper T lymphocytes (CD4). Immune sys-
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Abstract
Background: Immunodeficiencies should be suspected in cases of primary identified bronchiectasis in adults. Moldova is among the countries with 
a continuous increase in the number of HIV-infected adults. Impaired immune system and chronic inflammation contribute to the progression of 
bronchiectasis in HIV patients. The aim of the study was to present the clinical, imaging, bacteriological peculiarities and outcomes in adult patients 
with bronchiectasis and HIV/AIDS infection. 
Material and methods: This case series involved 11 patients with HIV/AIDS and bronchiectasis, selected from a prospective study conducted on 490 
patients diagnosed with non-cystic fibrosis bronchiectasis in a tertiary care hospital, between 2015–2019. Clinical, microbiological and radiological data, 
associated comorbidities and severity scores were analysed. Statistical analysis was performed using the SPSS 23 program. 
Results: The mean age was 39 years (range 25-65 years), with a male predominance (54%). A CD4 count <200 cells/mm3 was identified in 6 cases. The 
mReiff score (6.8±4.6) showed a significant correlation with Bhalla score (9.72±4.5), r=0.66 (p<0.05). BSI score (11.7±3) reflects better the severity of 
the disease, showing a significant correlation with the Bhalla imaging score (r=0.62, p<0.05). Assessing the impact of comorbidities (BACI index 5.4±4.3 
and Charlson index 6.9±1.3), the BACI index better reflected the severity of the disease in this group of patients, demonstrating a strong correlation with 
BSI (r =0.62, p<0.05). Only 3 patients (27%) were over 1-year follow-up.  
Conclusions: Bronchiectasis is one of the common pulmonary manifestations of HIV/AIDS infection, being responsible for a number of chronic respiratory 
symptoms and the risk of premature death.
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tem damage accompanied by chronic inflammation contrib-
utes to the progression of bronchiectasis in HIV patients [5, 
6], although in adult patients evidence is provided in favour 
of multifactorial involvement in both etiology and progres-
sion of bronchial wall lesions [5, 7]. More publications come 
up with arguments that show damage not only to the im-
mune response (from helper T lymphocyte deficiency, im-
paired local response of macrophages and monocytes), but 
also the direct effect on bronchial walls due to intercurrent 
infections (pneumonia or tuberculosis) and the association 
of chronic obstructive pulmonary disease in adult patients 
with bronchiectasis and HIV infection [5, 7, 8].
The study aims to present the clinical, imaging, bacte-
riological peculiarities and outcomes in adult patients with 
bronchiectasis and HIV/AIDS infection. 
Material and methods
A series of cases diagnosed with HIV/AIDS infection 
and bronchiectasis selected from the prospective study that 
included a group of 490 adult patients with non-cystic fi-
brosis (NCF) bronchiectasis evaluated at Chiril Draganiuc 
Hospital during 2015-2019. Each patient signed the in-
formed consent. Demographics, clinical characteristics, 
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biological, imaging, and microbiological data (bacteriologi-
cal examinations of sputum and bronchoalveolar lavage) 
were obtained and summarized in tables 1-4. The disease 
outcomes were analysed up to 1 year after being included 
in the study. HIV infection was confirmed by the positive 
WESTERN BLOT test, performed after obtaining two HIV-
positive ELISA tests. All patients underwent the thoracic 
high-resolution computed tomography (HRCT) scan that 
assessed the morphology of bronchial dilatations (cylindri-
cal, varicose and cystic), their distribution and the associ-
ated imaging lesions (cavities, calcification of lymph nodes, 
parenchymal calcifications, interstitial or consolidation 
syndromes). The Reiff (modified Reiff) [9, 10] and Bhalla 
[11] imaging scores were calculated. Bronchiectasis severity 
was evaluated using BSI (Bronchiectasis Severity Index) and 
FACED scores [12, 13]. Imaging signs of pulmonary hyper-
tension on thoracic HRCT were also evaluated. Validated 
measuring instruments were used to assess comorbidities 
and their impact on the evolution of the disease, namely 
the Charlson Comorbidity Index [14] and the BACI index 
(Bronchiectasis Aetiology and CO-Morbidity Index) [15].
Table 1
Demographic characteristics and comorbidities of HIV/AIDS patients with bronchiectasis
Age /Gender / 
Environment U/R
BMI, kg/m2 Smoker/SI Migrant worker Comorbidities
Pt. 1 26/M/R 17.3 Yes/10 p/y Yes, Russia Oropharyngeal candidiasis
Wasting syndrome








Pt. 3 35/F/R 19.8 No No Pneumocystis pneumonia
Multiple lung abscesses
Anaemia




Pt. 5 22/M/R 20.1 No No Anaemia
Pneumocystis pneumonia




Pt. 7 65/F/R 22.6 Yes/20p/y No Pulmonary cryptococcosis
Anaemia



















note: U – urban, R – rural; SI – smoking index; p/y – pack/years.
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Results
The prevalence of patients with bronchiectasis and HIV/
AIDS infection in the group of patients with non-cystic fi-
brosis bronchiectasis (490 patients) was 2% (11 patients). 
The mean age was 39.2±13.5 (26-65) years, 63% – under 
35 years old, 6 male patients (54%). No patient was a drug 
user, whereas 82% came from rural areas and 73% (8 pa-
tients) were married. Migrant worker status was identified 
in 64% of cases (tab. 1), migration to Russia being the most 
frequently reported (6 patients). All patients were hospital-
ized at least once during the last year in the departments 
of district medical facilities due to respiratory infections of 
unspecified etiology and diarrheic syndrome of unspecified 
etiology. Only two patients knew their HIV-infected status 
(though didn’t use antiretroviral treatment) at the time of 
being included in our study, 82% have been primarily diag-
nosed with HIV/AIDS. All patients were at the last stage of 
HIV infection (clinical category C) with multiple comorbid-
ities (tab. 2) and severe weight deficit, the mean BMI (body 
mass index) being of 17.4±3.4 kg/m2. Only 3 patients (27%) 
had a BMI above 18.5 kg/m2 (tab. 1). Out of 7 patients in 
whom the level of CD4 lymphocytes was evaluated (mean 
82±125/ mm3, range 4-350), 6 patients had a level below 
200/mm3 (3 cases had a critical level ≤ 5/mm3 and also had 
more severe lung lesions). Cough with purulent sputum was 
identified in all cases (7 patients reported amounts of more 
than 50 ml of sputum/24 hours) and 4 patients had sever-
al episodes of hemoptysis. Most cases showed significant 
co-morbid conditions. Anaemia was found in 10 patients 
(91%), the most severe cases  (haemoglobin level below 70 
g/l) were  associated with more extensive lung changes and 
chronic diarrhea. 
The assessment of the impact of comorbidities on the 
severity of bronchiectasis revealed the BACI index 5.4±4.3 
and the Charlson index 6.9±1.3. The BACI index better 
reflects the severity of the disease in patients with bron-
chiectasis and HIV/AIDS infection demonstrating a strong 
correlation with BSI (r=0.62, p <0.05).
The analysis of the thoracic HRCT scans showed an ex-
tremely polymorphic nature of the imaging lesions (tab. 3) 
at the time of inclusion in the study. The predominance of 
tubular (cylindrical) bronchiectasis was recorded (fig. 1-3). 
Six patients presenting exclusively cylindrical type of bron-
chiectasis, localized in all lobes revealed a 6-pont mReiff 
score and only 4 patients (36%) presented a score below 6 
points. The severity of bronchiectasis extension was high-
lighted by the mReiff imaging score (6.8±4.6 points), which, 
although simplified, showed a strong correlation with the 
Bhalla score (9.72±4.5; r=0.66; p <0.05).
Bronchiolitis imaging features were present in 5 patients 
(fig. 1, 3). Only one patient presented lung parenchyma 
calcifications, and another one showed calcifications in the 
bronchial walls (fig. 3). Imaging signs of pulmonary hyper-
tension (HTP) with pulmonary artery trunk diameter over 
27 mm and pulmonary artery diameter ratio to ascending 
aortic diameter above 0.9 were present in 3 patients (fig. 4). 
Analysing the BSI (11.7±3) and FACED (2.9±0.9) severity 
scores, BSI better reflects the severity of the disease in this 
etiological group of NCF bronchiectasis, and a good cor-
relation with the Bhalla imaging score was demonstrated 
(r=0.62, p <0.05).
Imaging signs suggestive of pneumonia caused by 
Pneumocystis jiroveci were identified in 7 patients (fig. 1), 
whereas the bacteriological confirmation was obtained only 
Table 2
Individual characteristics and outcomes of HIV-infected patients with bronchiectasis





antiretroviral treatment initiated during 
hospitalization
*Deceased (D)/Survived (S)
Pt. 1 Yes N/D 7 days/No S
Pt. 2 Yes N/D 14 days /No S
Pt. 3 No 5 36 days /No D
Pt. 4 Yes 5 12 days /No D
Pt. 5 Yes 122 18 days /No D
Pt. 6 Yes N/D 7 days /No D
Pt. 7 Yes N/D 29 days /No D
Pt. 8 No 4 38 days /Yes D
Pt. 9 Yes 39 21 days /Yes S
Pt.10 No, he has known about HIV 
status for 3 years
350 32 days /No D
Pt.11 Yes 50 8 days /No D
note: N/D – No data
* – Deceased (D)/Survived (S) one year after being included in the study.
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in one case (tab. 3, 4). It is still challenging to identify the 
pathogens responsible for pulmonary infections in severely 
immunocompromised patients, requiring the exclusion 
of opportunistic infections, fungal infections, mycobacte-
ria, and viruses in addition to Gram-positive and Gram-
negative pathogenic bacteria. 
Fig. 1.  Chest HRCT images of patient 1
Thoracic high-resolution CT in coronal (A, B) and axial (C, D) 
reconstructions of a 26-year-old man primarily diagnosed with HIV/
AIDS shows bilateral cylindrical bronchiectasis and bronchial wall 
thickening that is more prominent in the lower lobes. A number of areas 
demonstrating the “signet ring” and the “tram tracks” signs, or lack of 
tapering when viewed in longitudinal cross-section (some of them are 
amputated due to endobronchial secretions). The presence of “ground 
glass” opacities was recorded that might be the imaging expression of 
an opportunistic infection (P. jiroveci) that was not actually confirmed 
in this case.
Fig. 2.  Chest HRCT images of patient 4
Axial lung window HRCT sections (A, B, C) of a 32-year-old woman 
showing more severe bronchial dilatations (varicose and cystic) in the 
lingual segments (C). Tubular bronchiectasis was identified in the right 
upper lobe (A) as well as in the immediately subpleural areas of the left 
lung. The hypotrophy of the muscle and of the subcutaneous adipose tissue 
at the level of the thorax could be seen, the patient being with the lowest 
BMI 11 kg/m2 (33 kg at a height of 175 cm) among all the patients included 
in the study. There was an evidence of dilation of the oesophagus (A).
Fig. 3.  Chest HRCT images of patient 7
HRCT images of the chest in the oldest patient aged 65 from this series, 
diagnosed primarily with HIV/AIDS infection, showing bilateral 
tubular bronchiectasis. There are focal areas of decreased attenuation 
with a mosaic aspect of the lung fields (B, C), findings consistent with 
constrictive obliterative bronchiolitis.  Bronchial walls and aortic arch 
calcifications were recorded (A, C).
Table 3 















Pt. 1 RUL, RML, RLL, LUL, lingula, 
LLL/ tubular
6 7 Yes No Yes No
Pt. 2 RUL, RML, RLL, LUL, lingula, 
LLL/ tubular
6 7 No No No No
Pt. 3 RUL, RML, RLL, LUL, lingula, 
LLL/ tubular, cystic
18 14 No No No Yes
Pt. 4 RUL, RML, RLL, LUL, lingula, 
LLL/ tubular, cystic
8 16 No Yes Yes No
Pt. 5 RUL, RML, RLL, LUL, lingula, 
LLL/ tubular
6 6 Yes No Yes No
Pt. 6 RLL, LUL, lingula, LLL/ 
tubular, cystic
6 10 No Yes Yes No
Pt. 7 RLL, lingula, LLL/ tubular 3 10 Yes No Yes No
Pt. 8 RUL, RLL, LLL/ tubular, cystic 5 13 Yes No No No
Pt. 9 RUL, LUL/ tubular 2 4 No Yes Yes No
Pt.10 RUL, RML, RLL, lingula, LLL/ 
tubular, cystic
12 16 Yes No No Yes
Pt.11 RUL, RML, LUL/ tubular 3 4 No No Yes Yes
note: RUL – right upper lobe, RML – right middle lobe, RLL – right lower lobe, LUL – left upper lobe, LLL – left lower lobe, PHT – pulmonary hypertension, 
CT – computer tomography, PA:Ao ratio – ratio of pulmonary artery diameter to ascending aortic diameter.
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Fig. 4.  Chest HRCT images of patient 10
Chest HRCT images of a 46-year-old patient, being HIV- infected 
for 3 years (without antiretroviral therapy) showed an extensive lung 
damage, the upper right lobe being replaced by a cavity (A-C), with an 
intracavitary content, (suggestive of fungus ball). Multiple tubular and 
cystic bronchiectasis, some with hydroaeric level, more prominent on 
the right. Dilatation of the pulmonary artery (2.95 cm) was noted in 
relation to the ascending aorta (D). Ratio of pulmonary artery diameter to 
ascending  aortic diameter  was 1.2 (> 0.9 suggestive of pulmonary 
hypertension).
Bacteriological confirmation of M. tuberculosis infection 
was confirmed in none of the suspected patients; however, 
in 4 cases presenting cavitary lesions and/or consolidations, 
the diagnosis of pulmonary tuberculosis was established 
based on clinical and radiological criteria. Two patients 
could not tolerate the anti-tuberculosis medication due to 
its side effects. Fungal infections viz.  Cryptococcus neofor-
mans was identified in 3 cases and Candida spp- in 7 cases 
(tab. 4).
Only 3 patients (27%) survived one year after being in-
cluded in the study and continue the antiretroviral treat-
ment (ART) and 2 patients died during hospitalization (pa-
tient 7 and patient 10).
Discussion
The prevalence of patients with immunodeficiencies in 
the aetiological structure of NCF bronchiectasis cases varies 
from 6% to 14% in adults, being higher among children 20–
34% [16]. Recurrent respiratory tract infections, both viral 
and bacterial, along with HIV infection cause a decrease in 
innate immunity (due to a progressive loss of CD4 cells), 
which yields a persistent inflammatory state in the lower 
respiratory tract. Furthermore, in these patients, HIV infec-
tion may cause an inflammatory obliterative bronchiolitis, 
which would facilitate and contribute to the remodelling of 
the airways and the development of bronchiectasis [17].
Bronchiectasis is a progressive airway disease, anatomi-
cally defined by abnormal and progressive dilation of the 
bronchi, clinically manifested by persistent cough, sputum 
production, and recurrent respiratory tract infections, that 
are considered one of the most important aetiological fac-
tors in the development of bronchiectasis in HIV infected 
patients [17]. Microbial toxins and persistent inflamma-
tion compromise mucociliary clearance, which leads to 
increased susceptibility for microbial colonization, and 
Table 4
Microbiology data and diagnosticated opportunistic infections
Sputum cultures results
Bacteriological confirma-





Pt. 1 Candida albicans No No No
Pt. 2 Cryptococcus neoformans
Candida albicans
No No No
Pt. 3 S. aureus
E. coli
Candida albicans
No Yes, anti-TB treatment not 
tolerated
Yes
Pt. 4 Streptococcus gr D No Yes, anti-TB treatment 
refused
No
Pt. 5 Streptococcus gr D No No Yes
Pt. 6 Kl. pneumoniae
Candida krusei
No No Yes
Pt. 7 Cryptococcus neoformans No No Yes
Pt. 8 Cryptococcus neoformans
Citrobacter freundii
No Yes Yes
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create a self-perpetuating cycle [18]. Malnutrition, aspira-
tion pneumonitis due to gastroesophageal reflux disease, 
esophageal candidiasis are among the multiple factors that 
have been incriminated to complement the appearance of 
bronchiectasis in this group of patients [18-20].
Patients with HIV infection became a common reality in 
daily clinical practice of a general physician and of a pneu-
mologist as well. As the life expectancy of HIV-infected pa-
tients increased due to prevention and treatment of oppor-
tunistic infections, an early recognition of bronchiectasis 
and its associated features may have an important role for 
disease outcome. The key element for the diagnosis of bron-
chiectasis is the imaging technique. Thoracic HRCT scan, 
replacing the more invasive bronchography, is considered 
more sensitive to identify and assess the severity of bron-
chiectasis. 
Plenty of scientific papers have been published, describ-
ing pulmonary complications in HIV-infected patients, 
most of them including advanced immunosuppression 
cases, have focused on the evaluation and treatment of in-
fections with opportunistic germs. First studies presenting 
bronchiectasis in HIV-infected patients included a small 
series of cases, Holmes and co-authors published the first 
5 cases in 1992 [5, 21, 22]. Several authors have conclud-
ed that acute bronchitis is the most common pulmonary 
manifestation in HIV-infected patients and retrospective 
studies have shown that in AIDS patients bronchiectasis 
has a higher incidence [19, 23]. Similar to the results from 
the case series analysed by McGuinness (12 patients) [22] 
in our study, the airway lesions, as well as those identified 
in the lung parenchyma, were found to be much more ex-
tensive than would have been expected according the his-
tory of lung infections reported by patients. Verghese and 
co-authors concluded that recurrent bacterial infections 
(especially S. aureus, H. influenza, B. cepacia, and S. pneu-
moniae) contribute to the development of bronchiectasis in 
HIV-infected individuals much more frequently than pre-
viously considered [21].
In 1997 King and co-authors, analysing chest CT images 
of a group of 50 HIV-infected patients (without history of 
AIDS or lung infections until inclusion in the study) and 
another group of 11 HIV-negative control subjects, demon-
strated the presence of bronchiectasis in 36% of HIV infect-
ed patients and none in HIV-negative subjects. The authors 
hypothesised that lung and airway lesions in HIV-infected 
patients were present before the onset and development 
of lung infectious complications. Bronchial dilatation was 
found to be caused by bronchiolitis obliterans, elevated level 
of neutrophils in the airways and lymphocytic interstitial 
pneumonia [23].
Despite significant progress in understanding HIV in-
fection, including prevention strategies, chemoprophylaxis, 
and antiretroviral therapy, the incidence of HIV-related dis-
eases remains high in Moldova [1, 2]. Although the patients 
included in our study had a history of lung infections, the 
diagnosis, evaluation of the etiology and severity of bron-
chiectasis were neglected, most patients being identified 
with severe lung damage at the stage of establishing HIV 
status. Among the pulmonary complications, HIV/AIDS 
patients showed a higher occurrence for infections (espe-
cially pulmonary tuberculosis, pneumocystis pneumonia 
and various other opportunistic infections) thus, the deve-
lopment of bronchiectasis might be accelerated in this pa-
tient population.
Patients often underestimate their symptoms and refer 
to a doctor at the stage of advanced disease with limited 
management opportunities. Unfortunately, even after estab-
lishing the diagnosis of HIV/AIDS infection in the patients 
of our study, in some cases it was not possible to initiate 
ART, due to various difficulties (wasting syndrome, dyspep-
tic syndrome, religious and cultural considerations, poverty, 
inadequate referral system and poor adherence to treat-
ment) which may have contributed to a high mortality rate, 
thus leading to 73% of deaths in this case series. Countries 
with limited resources face more difficulties in managing 
chronic diseases and bronchiectasis and HIV/AIDS are no 
exception. It would be advisable to test for HIV infection as 
part of the diagnostic process not only the patients with HIV 
risk factors, but also the group of primary identified patients 
with bronchiectasis, especially in countries with high inci-
dence of HIV infection, such as the Republic of Moldova.
Conclusions
Bronchiectasis is one of the common pulmonary mani-
festations of HIV/AIDS infection, being responsible for a 
number of chronic respiratory symptoms and a risk factor 
for premature death.
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